Pureos Bioventures’ Post

Pureos Bioventures brought together Uyen Huynh-Do, Erik van den Berg, guido magni, Roberto Iacone in our inspiring LP event to discuss current challenges and the promising future of kidney therapies. In her keynote presentation Uyen Huynh-Do, Professor Department of Nephrology at Inselspital Bern, introduced Chronic Kidney disease (CKD) and current challenges and developments in nephrology. Erik van den Berg, CEO of Memo Therapeutics AG, shared his vision for developing a first-in-class therapy against BK Virus: a serious threat for kidney transplant patients. Guido Magni, CMO of River Renal, shared his approach to setting up clinical stage biotechs and for treating orphan diseases in the renal space. The group was joined by Roberto Iacone, CEO of Alentis Therapeutics, in the panel to discuss the biotech scene in Switzerland, different company models for biotech companies, and the current financial environment in Europe and the US. This event reminded us of the incredible progress we are making in the fight against kidney diseases. Let's continue to work together to make a difference in the lives of patients with kidney disease worldwide!

Meet the Pureos Bioventures Team at the Swiss Biotech Day in Basel on April 22-23 and join our Emerging Company Stream in the afternoon. Swiss Biotech Association

East - West Biopharma Summit in #Singapore Great conference to build and strengthen relationships between the biopharma community from East and West. Our partner Dominik Escher shared his experience of building and financing biotech start-ups and how to use platform technologies to develop products that will help patients in the future. He also met with many local biotechs to help build a strong biotech industry.

We are very sad about the tragic accident and the sudden loss of our friend and former colleague Luigi Costa. Our thoughts are with his family and loved ones in these sad times. We and many in our industry will miss him and his friendly and cheerful nature. Luigi, it was great pleasure for us to have known you. 

We are proud to share the news of our portfolio company PulseSight Therapeutics that launches to advance non-viral gene therapies with disruptive minimally-invasive delivery technology for severe retinal diseases. • Unique proprietary non-viral gene therapy platform with minimally invasive delivery technology providing long lasting gene expression and favorable distribution in the retina. • Focus on age-related macular degeneration (AMD) including wet AMD and late-stage dry AMD/geographic atrophy (GA), a rapidly growing market expected to reach $27.5bn by 2031. • A substantially de-risked platform and two first-in-class gene therapies heading to the clinic, having the potential to become future blockbusters. • Highly experienced management team and Board of Directors – Judith Greciet, CEO and Dirk Sauer, ex-Novartis Global Development Unit Head, Ophthalmology, as Independent Chair of the Board. • Compelling investment case with a Series A capital raising underway, backed by two ophthalmology experienced venture investors, Pureos Bioventures and ND Capital. https://lnkd.in/dYhtfWdS

Our portfolio company LAVA Therapeutics N.V. announces a collaboration with Merck & Co., Inc. to evaluate Lava-1207 in combination with pembrolizumab. This cooperation will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with prostate cancer (mCRPC). We are looking forward continuing the journey to bring new therapies to patients with mCRPC. https://lnkd.in/eBNc9ZjA

Pureos Bioventures portfolio company AM-Pharma started testing ilofotase alfa, as a preventive treatment for cardiac surgery-associated renal damage in a clincal Phase 2 study. A high medical need indication. Fingers crossed that ilofotase will help to prevent CSA-RD! https://lnkd.in/eykpXE5R

Exciting update from our portfolio company Ariceum Therapeutics! Congratulations for filing a CTA to test the first-in-class Iodine-123 labelled PARP inhibitor in patients with recurring glioblastoma – an indication in desperate need of novel therapies. 

Start your year with listening to the latest episode of The Drug Discovery World Podcast! Manfred Ruediger, CEO of our portfolio company Ariceum Therapeutics talks about their pipeline of radiopharmaceutical drugs for cancer patients and the future for the company.   Do not miss: https://lnkd.in/eGcPJwGK

We welcome William Pao, MD, PhD as Independent Board Member to our portfolio company Alentis Therapeutics. William’s deep experience in drug development and oncology as former Chief Development Officer at Pfizer and Head of pRED at Roche will be invaluable to bring anti-CLDN1 antibodies to patients. https://lnkd.in/egMvNkXW